fenofibric acid / Generic mfg. - LARVOL DELTA

Preparation and Characterization of Fenofibric Acid-Loaded Electrospun Fibrous Mats. (PubMed, Nanomaterials (Basel)) - "In vitro dissolution tests in artificial saliva showed a markedly enhanced release rate of fenofibric acid from the fibrous mats compared with the pure crystalline form, indicating a significant improvement in apparent solubility. These findings highlight the potential of PVP-based electrospun fiber formulation as an efficient carrier for the active metabolite of fenofibrate."

Journal

Potential of Fenofibric Acid as Topical Eye Drops for Management of Dry Eye Syndrome. (PubMed, Pharmaceutics) - "A regimen of twice-a-day eyedrops (500 µg/mL) demonstrated good ocular safety and therapeutic efficacy on the BAC-induced dry eye model in SD rats, with significant effects on the reduction in corneal edema and on preventing the loss of goblet cells from dry eye pathology. These findings strongly suggest that FFA eye drops at a concentration of 500 µg/mL may effectively control ocular surface inflammation and relieve dry-eye discomfort."

Journal • Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology

Drugs for hypertriglyceridemia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dyslipidemia • Hypertriglyceridemia

Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants. (PubMed, Transl Clin Pharmacol) - "Plasma concentrations of atorvastatin and 2-hydroxy (2-OH) atorvastatin were measured for 48 h in all periods, and fenofibric acid for 72 hours in the first two periods. The findings support its use as an alternative to improve medication adherence in patients with mixed dyslipidemia requiring dual lipid-modifying therapy. Clinical Research Information Service Identifier: KCT0010666."

Journal • PK/PD data • Cardiovascular • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

Effect of insect cuticular compounds on appressorium formation and metabolic activity in Metarhizium anisopliae. (PubMed, Front Microbiol) - "The results showed that amino acid compounds L-aspartic acid and glycyl-L-phenylalanine, amine-class compound L-sorbitol, aromatic compounds and fenofibric acid, and organic acid 4-(aminomethyl) benzoic acid promoted spore germination and appressorium formation (p ≤ 0.05)...After appressorium formation, L-aspartic acid further promotes fungal cuticle penetration, accelerates in-host colonization, and facilitates toxin synthesis to kill the host, thereby improving the infectivity of M. anisopliae in multiple ways. This study provides a theoretical basis for in-depth investigations into the infection mechanism of M. anisopliae and the mechanistic role of appressorium during infection."

Journal • Infectious Disease

Multifunctional biohybrid nanoplatform interferes electron transport chain amplifying mitochondrial metabolism-mediated anti-tumor therapy. (PubMed, Mater Today Bio) - "In this study, a multifunctional MOF@TK nanoplatform with intrinsic activity was innovatively synthesized by Zinc (Zn2+) and Fenofibric acid (FFa), which was modified through tumor cell membranes transfected with PD-1 (CMP-MOF@TK) to efficaciously induce mitochondrial dysfunction with ETC inactivation and amplified anti-tumor response...In addition, the mitochondrial damage-mediated ICD of tumor cells promoted the increased HMGB1 and CRT in the cytomatrix, and tumor cell membrane transfection of PD-1 effectively down-regulated T cell-mediated immune tolerance, effectively activating anti-tumor immune response. In a word, this work offers a potent strategy for developing anti-tumor platforms with multiple functionalities, which provides translational promise for mitochondrial metabolism interference based on ETC dysfunction to strengthen the anti-tumor effect."

Journal • Melanoma • Metabolic Disorders • Oncology • Solid Tumor • HMGB1 • PD-1

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia (clinicaltrials.gov) - P4 | N=56 | Recruiting | Sponsor: Seoul National University Bundang Hospital | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Determination of fenofibric acid in saliva and exhaled breath condensate samples using metal- organic frameworks based dispersive micro solid phase extraction coupled to HPLC-PDA. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "This study introduces the use of an ultrathin nickel-benzene dicarboxylate metal-organic framework (Ni-BDC-MOF) for the extraction of fenofibrate. The method's relative standard deviations (RSDs) at 5 ng/mL, 50 ng/mL and 200 ng/mL were below 11.3%, indicating good precision. This simple, reliable, and cost-effective method was successfully applied to analyze fenofibrate in exhaled breath condensate and saliva samples."

Journal

MEMMAT: Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors (clinicaltrials.gov) - P2 | N=232 | Recruiting | Sponsor: Medical University of Vienna | N=100 ➔ 232

Enrollment change • Brain Cancer • CNS Tumor • Ependymoma • Medulloblastoma • Oncology • Solid Tumor

Assessing the real-world safety of fenofibric acid for hyperlipidemia: results from WHO-VigiAccess and FAERS databases. (PubMed, Front Med (Lausanne)) - "In addition to the known adverse reactions, this study has identified numerous potential adverse drug reactions associated with fenofibric acid. Although these findings require further validation through subsequent clinical trials, they provide valuable safety information for clinicians to consider when evaluating adverse effects in patients treated with fenofibric acid."

Journal • Real-world evidence • Allergy • Dyslipidemia • Fatigue • Gout • Hypertriglyceridemia • Hypoglycemia • Inflammatory Arthritis • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Pancreatitis • Renal Disease • Rheumatology • PPARA

Nanoparticles-mediated mitochondrial relocation of lipid-lowering drugs shape energy metabolism to conquer acquired immune resistance. (PubMed, Drug Resist Updat) - "Then, it was also revealed that clinical usable lipid-lowering drugs with mitochondria oxidative phosphorylation (OXPHOS) and glycolysis inhibiting capacity, like fenofibric acid (FFA), exhibited desired programmed death ligand-1 (PD-L1) and CD276 co-suppression capacity...Moreover, the combination therapy of IR-FFA@Alb nanoparticles and radiotherapy (RT) effectively avoid the frequently occurred immune tolerance phenomenon of RT by co-depression CD276 and PD-L1. These results altogether showed the possibility of using lipid-lowering drugs as multi-functional immune checkpoint inhibitors to sensitize tumor therapy."

IO biomarker • Journal • CNS Disorders • Depression • Oncology • Psychiatry • CD276 • PD-L1

Antiepileptic drugs and lipid-lowering agents in surface water in Colombia: occurrence, ecological threat, and removal strategies. (PubMed, Environ Sci Pollut Res Int) - "The findings revealed the presence of antiepileptic drugs such as carbamazepine (CBZ), 10,11-dihydro-10,11-dihydroxycarbamazepine (CBZ-Diol), and gabapentin (GBP). Detected lipid-lowering agents included fenofibric acid (FFA) and gemfibrozil (GFZ)...Findings underscore the need for pharmaceutical monitoring and management in water sources. Removing these compounds remains challenging due to their variable removal patterns, necessitating the development of effective mitigation strategies."

Journal

Design, synthesis, and evaluation of small molecule modalities for diabetic retinopathy (ACS-Fall 2025) - "Fenofibric acid, the active metabolite of fenofibrate and a known peroxisome proliferator-activated receptor alpha (PPARa) agonist, significantly reduces DR progression, as demonstrated in two independent clinical trials (FIELD and ACCORD). 3) Dual PPARα/RXRα agonism: due to the permissive nature of this heterodimeric pairing, we are pursuing dual agonists, which are expected to enhance potency and therapeutic outcomes. Progress in all three areas will be presented."

Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • PPARA • STING

Next generation approaches to small molecule PPARα agonism for retinal diseases (ACS-Fall 2025) - "PPARα has been clinically validated as a viable target for DR, as Fenofibrate (Feno), a clinically approved drug for hyperlipidemia, exhibited robust protective effects against disease progression and retinal neovascularization (NV) in type 2 diabetic patients. The protective effects of Feno on retinal inflammation, neuroprotection, NV and DR are unrelated to its lipid-lowering activity but rather result from agonism of PPARα by its major metabolite, fenofibric acid (FA)...In part I, the development of orally bioavailable NFPαAs will be discussed along with new data on formulations that provide >6-months of efficacy after a single intravitreal injection in animal models. In part II, data from a new initiative aimed at leveraging polypharmacology will be reported with the story of BH400, a dual PPARα (agonist) and STING (inhibitor) modulator."

Age-related Macular Degeneration • Diabetes • Diabetic Retinopathy • Dyslipidemia • Inflammation • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus • PPARA • STING

PPAR-mediated reduction of lipid accumulation in hepatocytes involves the autophagy-lysosome-mitochondrion axis. (PubMed, Ann Med) - "HepG2 cells were treated with oleate/palmitate (O/P) to induce lipid accumulation and exposed to the PPARα agonist fenofibric acid, the γ agonist pioglitazone, the δ agonist seladelpar, or the dual α/γ agonist saroglitazar. All PPAR agonists were able to promote the clearance of lipids in cells loaded with long-chain fatty acids. The key role of acid hydrolysis to generate fatty acids, which can be then catabolized in the mitochondria, and the ability of the PPAR system to sustain each phase of this clearing process were elucidated."

Journal • PPARA • TFEB

Fenofibrate inhibits activation of cGAS-STING pathway by alleviating mitochondrial damage to attenuate inflammatory response in diabetic dry eye. (PubMed, Free Radic Biol Med) - "This study aims to investigate the role of the cGAS-STING signaling pathway in diabetic dry eye disease (DDE) and further explore the therapeutic efficacy and underlying mechanism of fenofibric acid in DDE. Further investigation revealed that fenofibrate alleviated corneal inflammation in diabetic mice by inhibiting reactive oxygen species (ROS) production, restoring mitochondrial membrane potential, and suppressing the activation of the cGAS-STING signaling pathway. In conclusion, this study highlights the crucial role of the cGAS-STING signaling pathway in DDE and proposes that fenofibrate alleviates mitochondrial damage to inhibit this pathway, offering novel strategy for the treatment of DDE."

Journal • Diabetes • Dry Eye Disease • Inflammation • Keratitis • Metabolic Disorders • Ocular Inflammation • Ophthalmology • CGAS • STING

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver Disease. (PubMed, J Clin Pharmacol) - "In the phase 2a study, participants with hypertriglyceridemia and advanced fibrosis due to MAFLD were randomly assigned (1:1) fenofibrate 48 mg (n = 15) or fenofibrate 145 mg (n = 16) combined with firsocostat 20 mg, taken orally once daily for 24 weeks. In the phase 2a study, three participants had grade 3 hypertriglyceridemia. Fenofibrate was well tolerated, and modest differences were observed in fenofibric acid exposure in participants with mild hepatic impairment or advanced fibrosis due to MAFLD."

Journal • PK/PD data • Dyslipidemia • Fibrosis • Hepatology • Hypertriglyceridemia • Immunology • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Mitochondrial-Targeted Multifunctional Platinum-Based Nano "Terminal-Sensitive Projectile" for Enhanced Cancer Chemotherapy Efficacy. (PubMed, ACS Nano) - "Herein, a platinum-based terminal-sensitive projectile (TSB) which comprises a heterofunctional tetravalent platinum prodrug as the primary warhead, complemented by a guidance system incorporating triphenylphosphine (TPP) and a secondary warhead, FFa (Fenofibric acid) was developed...This design allows the TSB to be precisely targeted into intertumoral mitochondria as its targeting terminal, releasing free oxaliplatin (OXA) and FFa upon reaching its terminal destination...Furthermore, under near-infrared (NIR) irradiation, the IR780 component generates a phototherapeutic thermal effect and reactive oxygen species (ROS), which deplete intracellular glutathione (GSH) levels and facilitate Pt cross-linking with mtDNA. Both in vitro and in vivo studies have demonstrated that this comprehensive approach significantly enhances the sensitivity of tumor cells to platinum-based chemotherapeutic drugs."

Journal • Metabolic Disorders • Oncology

Significantly improving the solubility and anti-inflammatory activity of fenofibric acid with native and methyl-substituted beta-cyclodextrins via complexation. (PubMed, Sci Rep) - "The efficacy of FFA complexed with CDs in mitigating inflammation positions it as a promising new drug. Additionally, our findings reveal that incorporating FFA into the CD cavity as a drug release system enhances the pharmacological profile of this substance, FFA."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Pain • Rheumatology

AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Piedmont Healthcare | N=18 ➔ 0 | Terminated ➔ Withdrawn

Enrollment change • Trial withdrawal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

Administration time modify the anxiolytic and antidepressant effects of inulin via gut-brain axis. (PubMed, Int J Biol Macromol) - "Serum metabolomics analysis showed that the main differential metabolites, including fenofibric acid, 4'-Hydroxyfenoprofen glucuronide and 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione may be vital for the anxiolytic and antidepressant effects of different inulin treatment times. Our results suggested that inulin administration in the evening was more effective in alleviating the inflammatory response and improving amino acids metabolism. This study provides a new potential link between the microbiota-gut-brain axis and chrono-nutrition, demonstrating that a more appropriate administration time results in a better intervention effect."

Journal • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry • Transplantation

MEMMAT: Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Medical University of Vienna | Trial completion date: Apr 2026 ➔ Apr 2030 | Trial primary completion date: Apr 2026 ➔ Apr 2030

Trial completion date • Trial primary completion date • Brain Cancer • Ependymoma • Medulloblastoma • Oncology • Solid Tumor

A facile synthesis of 2-(4-((4-chlorophenyl)(hydroxy)methyl) phenoxy)-2-methylpropanoic acid: Metabolite of anti-hyperlipidemic drug Fenofibrate. (PubMed, Results Chem) - "The ketone group of fenofibric acid was reduced using sodium borohydride in one route whereas the hydrolysis of isopropyl ester of the reduced fenofibrate was achieved by the mild alkaline hydrolysis in the other path. Both the ways of synthesis furnished the desired compound in excellent yield and purity. The new synthetic congener was characterized by spectroscopic methods."

Journal

Fenofibric Acid has Distinct Molecular Location in Reconstituted Liver Membranes and Higher Affinity Compared to Pemafibrate (NLA 2024) - "Fenofibric acid had higher membrane affinity and more pronounced interactions in reconstituted liver membranes compared to pemafibrate. This may contribute to differences in pharmacologic properties and potential clinical outcomes."

Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • PPARA

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia (clinicaltrials.gov) - P4 | N=56 | Recruiting | Sponsor: Seoul National University Bundang Hospital | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Mar 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus